A carregar...
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
INTRODUCTION: In 2016, SB4 (Benepali(®)) became the first etanercept (ETN) biosimilar to obtain marketing authorisation in Europe. Despite robust analytical and clinical comparisons, outstanding questions remain on SB4 use in routine practice. METHODS: A systematic search for publications on real-wo...
Na minha lista:
| Publicado no: | Rheumatol Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Healthcare
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6702587/ https://ncbi.nlm.nih.gov/pubmed/31385263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-019-00169-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|